Who Paid My Doc
Asparlas
Drug Oncology
NDC 72694-515-01
General payments
$638,002
Research payments
$16,600,519
Through program year 2025, $638,002 in general payments and $16,600,519 in research payments were reported against Asparlas (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
14 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $97,482 | 320 |
| 2025 | Research | $4,435,700 | 425 |
| 2024 | General | $13,449 | 312 |
| 2024 | Research | $4,150,626 | 319 |
| 2023 | General | $99,134 | 383 |
| 2023 | Research | $3,662,830 | 15 |
| 2022 | General | $304,813 | 734 |
| 2022 | Research | $2,744,117 | 28 |
| 2021 | General | $73,743 | 83 |
| 2021 | Research | $1,017,503 | 20 |
| 2020 | General | $48,557 | 116 |
| 2020 | Research | $213,408 | 5 |
| 2019 | General | $823 | 17 |
| 2019 | Research | $376,334 | 6 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 29 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 34 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
1,965 general · 818 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.